Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Dermatology

The Atopic March and Long-Term Wellness

At a Glance

The atopic march is the progression from atopic eczema in childhood to other systemic conditions like food allergies and asthma. Early, aggressive skin barrier management and proactive treatments can help slow this progression while improving long-term health and sleep quality.

Living with atopic eczema is a long-term journey that requires looking beyond the skin’s surface. Because atopic eczema is a systemic condition, it can be the “opening act” for other allergic issues and can significantly impact your mental health and daily life [1][2].

The Atopic March

Many patients and parents are concerned about the atopic march—the clinical progression from atopic eczema in infancy to other allergic conditions later in life [1].

  • The Path: It typically moves from eczema to food allergies, followed by asthma and allergic rhinitis (hay fever) [1].
  • The Cause: This happens when allergens from the environment enter the body through the damaged (leaky) skin barrier and “train” the immune system to overreact, leading to systemic allergies [3][4].
  • Prevention: Early and aggressive management of the skin barrier may help slow or prevent this march. Some evidence suggests that targeted biologics, such as dupilumab, may reduce the risk of progressing to other allergic conditions in children [5][6].

Environmental Impact

Your surroundings play a major role in how often and how severely you flare. Research has identified specific environmental triggers that can worsen atopic eczema:

  • Pollutants: Chemicals like PFAS (found in some non-stick coatings and water-resistant materials) and air pollution have been linked to an increased risk of developing eczema and experiencing more severe symptoms [7][8].
  • Smoke: Exposure to second-hand smoke is strongly associated with both atopic dermatitis and hand eczema [9].
  • The Microbiome: Constant exposure to harsh household cleaners can disrupt the skin’s natural “good” bacteria, making it easier for “bad” bacteria to take over [10].

Long-Term Monitoring Strategy

Managing a chronic disease can be exhausting. To move from “panic mode” to “control mode,” doctors recommend using standardized tracking tools:

  • RECAP and ADCT: These validated scales allow you to objectively measure how well your eczema is controlled over time [11][12]. Instead of just looking at the skin today, they ask about your itch, sleep, and mood over the past week or month [13].
  • Proactive Therapy: Rather than waiting for a flare to appear, a “proactive” approach involves using a small amount of anti-inflammatory medication (like a topical steroid or calcineurin inhibitor) twice weekly on areas that usually flare, even if they look clear [14][15].

The Quality of Life Connection

The most significant long-term impact of atopic eczema is often not the rash itself, but the sleep disruption it causes [2]. Chronic itching leads to “micro-awakenings” throughout the night, which can result in:

  • Increased risk of anxiety and depression [16][17].
  • Behavioral and concentration issues in children [18].
  • Significant “caregiver burden” for parents who must also wake up to comfort a child [19].

Newer systemic treatments, including biologics and JAK inhibitors, have shown sustained success in improving not just the skin, but also sleep and overall mental health for those with moderate-to-severe disease [18][20].

Back to Home

Common questions in this guide

What is the atopic march?
The atopic march is the clinical progression of allergic diseases that often begins with eczema in infancy. Over time, patients may go on to develop food allergies, asthma, and allergic rhinitis as they get older.
Can you prevent eczema from turning into asthma or food allergies?
Early and aggressive management of the skin barrier can help slow or prevent the atopic march. Evidence also suggests that certain targeted biologic medications may reduce the risk of a child developing other allergic conditions later in life.
What environmental triggers make eczema worse?
Environmental factors like air pollution, specific chemicals, harsh household cleaners, and second-hand smoke can worsen symptoms. These triggers disrupt the skin's healthy bacteria and increase overall inflammation.
What is proactive therapy for eczema?
Instead of waiting for a rash to appear, proactive therapy involves applying a small amount of anti-inflammatory medication to areas that usually flare, even when they look clear. This twice-weekly routine helps prevent flares before they start.
Why does eczema cause sleep problems?
Severe itching causes constant micro-awakenings throughout the night, preventing deep rest. Over time, this chronic sleep disruption significantly increases the risk of anxiety, depression, and behavioral issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the severity of my (or my child's) eczema, what is our specific risk for the 'atopic march,' and how should we screen for asthma or food allergies?
  2. 2.Would starting a biologic therapy early help prevent the progression to other allergic conditions?
  3. 3.What is the best 'proactive' schedule for using topical medications to prevent a flare before it starts?
  4. 4.Given the sleep disruption we are experiencing, should we involve a sleep specialist or consider systemic treatments earlier?
  5. 5.Which environmental factors in our specific living area (like air quality or chemical exposures) should we be most concerned about?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Might biologics serve to interrupt the atopic march?

    Spergel JM, Du Toit G, Davis CM

    The Journal of allergy and clinical immunology 2023; (151(3)):590-594 doi:10.1016/j.jaci.2023.01.001.

    PMID: 36681581
  2. 2

    Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

    Simpson EL, Bieber T, Guttman-Yassky E, et al.

    The New England journal of medicine 2016; (375(24)):2335-2348 doi:10.1056/NEJMoa1610020.

    PMID: 27690741
  3. 3

    Antigen Protease Activity on Intact or Tape-Stripped Skin Induces Acute Itch and T Helper Sensitization Leading to Airway Eosinophilia in Mice.

    Kimitsu T, Kamijo S, Yoshimura T, et al.

    JID innovations : skin science from molecules to population health 2024; (4(1)):100239 doi:10.1016/j.xjidi.2023.100239.

    PMID: 38282648
  4. 4

    Indoor aeroallergens from American cockroaches and mites initiate atopic march via cutaneous contact in a murine model.

    Lee MF, Chu YW, Wu CS, et al.

    PloS one 2023; (18(7)):e0289138 doi:10.1371/journal.pone.0289138.

    PMID: 37498896
  5. 5

    Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.

    Lin TL, Fan YH, Fan KS, et al.

    Journal of the American Academy of Dermatology 2024; (91(3)):466-473 doi:10.1016/j.jaad.2024.05.029.

    PMID: 38878041
  6. 6

    Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review.

    Torres T, Mendes-Bastos P, Cruz MJ, et al.

    Dermatology and therapy 2025; (15(3)):579-597 doi:10.1007/s13555-025-01352-y.

    PMID: 39930311
  7. 7

    Exposure to per-and poly-fluoroalkyl substances and respiratory and skin effects in children and adolescents: A systematic review and meta-analysis.

    Hatem G, Faria AM, Pinto MB, et al.

    Journal of hazardous materials 2025; (491()):137978 doi:10.1016/j.jhazmat.2025.137978.

    PMID: 40120265
  8. 8

    Pollen Food Allergy Syndrome in Allergic March.

    Yasudo H, Yamamoto-Hanada K, Yang L, et al.

    Nutrients 2022; (14(13)) doi:10.3390/nu14132658.

    PMID: 35807837
  9. 9

    Associations of second-hand smoke exposure with hand eczema and atopic dermatitis among college students in China.

    Jing D, Li J, Tao J, et al.

    Scientific reports 2020; (10(1)):17400 doi:10.1038/s41598-020-74501-2.

    PMID: 33060809
  10. 10

    [Atopic eczema and microbiome].

    Reiger M, Schwierzeck V, Traidl-Hoffmann C

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(6)):407-415 doi:10.1007/s00105-019-4424-6.

    PMID: 31111169
  11. 11

    Measurement properties of patient-reported outcome measures for eczema control: a systematic review.

    Stuart BL, Howells L, Pattinson RL, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(10)):1987-1993 doi:10.1111/jdv.17335.

    PMID: 33977561
  12. 12

    Cross-Cultural Validation of the RECAP of Atopic Eczema Question-naire in a Swedish Population.

    Sigurdardottir G, Alsterholm M, Andersson CD, et al.

    Acta dermato-venereologica 2024; (104()):adv38889 doi:10.2340/actadv.v104.38889.

    PMID: 38898676
  13. 13

    Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study.

    Lee HJ, Woo Y, Lee YB, et al.

    Acta dermato-venereologica 2025; (105()):adv40704 doi:10.2340/actadv.v105.40704.

    PMID: 39936606
  14. 14

    Atopic eczema.

    Brown SJ

    Clinical medicine (London, England) 2016; (16(1)):66-9 doi:10.7861/clinmedicine.16-1-66.

    PMID: 26833520
  15. 15

    ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

    Wollenberg A, Christen-Zäch S, Taieb A, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(12)):2717-2744 doi:10.1111/jdv.16892.

    PMID: 33205485
  16. 16

    Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults.

    Strom MA, Fishbein AB, Paller AS, Silverberg JI

    The British journal of dermatology 2016; (175(5)):920-929 doi:10.1111/bjd.14697.

    PMID: 27105659
  17. 17

    Anxiety and Depression in Patients with Atopic Dermatitis in a Southeast Asian Tertiary Dermatological Centre.

    Lim VZ, Ho RC, Tee SI, et al.

    Annals of the Academy of Medicine, Singapore 2016; (45(10)):451-455.

    PMID: 27832219
  18. 18

    Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).

    Silverberg JI, Gooderham MJ, Paller AS, et al.

    American journal of clinical dermatology 2024; (25(3)):485-496 doi:10.1007/s40257-024-00853-4.

    PMID: 38528257
  19. 19

    Assessing the Clinical Efficacy of Dupilumab and Its Impact on the Quality of Life of Adult Atopic Dermatitis Patients: A Systematic Review.

    Krissheeven M, Nunkoo S, Ramanah M, et al.

    Cureus 2025; (17(2)):e79762 doi:10.7759/cureus.79762.

    PMID: 40161158
  20. 20

    Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).

    Simpson EL, Prajapati VH, Leshem YA, et al.

    Dermatology and therapy 2024; (14(5)):1127-1144 doi:10.1007/s13555-024-01157-5.

    PMID: 38696027

This page provides educational information about atopic eczema and the atopic march. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider regarding your specific symptoms and treatment options.

Get notified when new evidence is published on atopic eczema.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.